Profiles

Keywords
Last Name
Institution

Mary Jo Fidler

Concepts (264)

Concepts are derived automatically from a person's publications.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Carcinoma, Non-Small-Cell Lung
23
2021
374
4.280
Why?
Lung Neoplasms
25
2022
756
3.840
Why?
Antineoplastic Combined Chemotherapy Protocols
11
2021
405
1.700
Why?
Antineoplastic Agents
6
2022
274
1.260
Why?
Carcinoma, Squamous Cell
9
2019
207
1.020
Why?
Quinazolines
3
2012
27
1.010
Why?
Chemoradiotherapy
9
2016
69
0.980
Why?
Esophagectomy
1
2019
25
0.780
Why?
Sarcopenia
1
2019
34
0.750
Why?
Neoplasm Staging
17
2021
481
0.750
Why?
Esophageal Neoplasms
1
2019
61
0.740
Why?
Kidney Glomerulus
5
2019
96
0.720
Why?
Drug Resistance, Neoplasm
2
2018
76
0.690
Why?
Aged
35
2019
10295
0.670
Why?
Inflammation Mediators
1
2018
94
0.670
Why?
Radiotherapy, Conformal
2
2014
24
0.670
Why?
Amyloidosis
5
2018
29
0.660
Why?
Oropharyngeal Neoplasms
4
2019
23
0.650
Why?
Prognosis
15
2022
1028
0.640
Why?
Pneumonectomy
2
2015
90
0.640
Why?
Neoadjuvant Therapy
4
2016
71
0.630
Why?
Muscle, Skeletal
1
2019
385
0.600
Why?
ErbB Receptors
5
2018
78
0.580
Why?
Gene Dosage
2
2012
27
0.580
Why?
PTEN Phosphohydrolase
2
2011
12
0.560
Why?
Female
40
2022
18253
0.560
Why?
Middle Aged
33
2021
11209
0.550
Why?
Male
39
2021
17583
0.550
Why?
Humans
50
2022
31481
0.540
Why?
Social Class
1
2014
71
0.520
Why?
Kidney Diseases
5
2014
146
0.520
Why?
Kidney
5
2019
210
0.510
Why?
Glomerulonephritis
3
2019
27
0.490
Why?
Treatment Outcome
23
2021
3910
0.490
Why?
Antibodies, Monoclonal, Humanized
3
2019
136
0.480
Why?
Receptor, IGF Type 1
1
2012
21
0.470
Why?
Postoperative Complications
2
2019
1083
0.460
Why?
Survival Analysis
9
2021
379
0.450
Why?
Phosphatidylinositol 3-Kinases
1
2011
50
0.450
Why?
Immunotherapy
2
2021
74
0.420
Why?
Retrospective Studies
19
2022
3591
0.390
Why?
Cyclooxygenase 2
2
2014
33
0.390
Why?
Neoplasm Recurrence, Local
4
2021
236
0.370
Why?
Survival Rate
8
2018
465
0.360
Why?
Glomerulonephritis, Membranous
2
2021
8
0.360
Why?
Gastrointestinal Hemorrhage
1
2008
29
0.350
Why?
Glomerulonephritis, Membranoproliferative
2
2018
5
0.330
Why?
Kidney Transplantation
5
2019
141
0.330
Why?
Head and Neck Neoplasms
2
2021
137
0.320
Why?
Adenocarcinoma
3
2018
237
0.310
Why?
Proteomics
3
2018
80
0.310
Why?
Adult
17
2021
9779
0.290
Why?
Induction Chemotherapy
2
2016
14
0.290
Why?
Follow-Up Studies
8
2018
2028
0.280
Why?
Databases, Factual
6
2019
391
0.270
Why?
Radiotherapy, Intensity-Modulated
2
2014
39
0.260
Why?
Immunohistochemistry
4
2021
494
0.260
Why?
Kaplan-Meier Estimate
6
2021
230
0.260
Why?
Disease-Free Survival
6
2018
241
0.260
Why?
Combined Modality Therapy
6
2019
456
0.250
Why?
Biopsy
7
2019
283
0.250
Why?
Molecular Targeted Therapy
2
2015
39
0.250
Why?
Aged, 80 and over
11
2019
5234
0.240
Why?
Mutation
3
2018
464
0.240
Why?
Programmed Cell Death 1 Receptor
2
2021
23
0.240
Why?
Maytansine
1
2022
3
0.240
Why?
Cohort Studies
7
2021
2014
0.240
Why?
Immunoconjugates
1
2022
13
0.240
Why?
United States
5
2019
2539
0.240
Why?
Immunosuppressive Agents
3
2019
163
0.230
Why?
Thoracic Neoplasms
1
2022
10
0.230
Why?
Immunoglobulin Light Chains
2
2011
9
0.230
Why?
N-Acetylglucosaminyltransferases
1
2021
3
0.220
Why?
Weight Gain
2
2012
70
0.220
Why?
Carcinoma, Large Cell
2
2018
18
0.210
Why?
Lupus Nephritis
1
2021
35
0.210
Why?
Chemoradiotherapy, Adjuvant
3
2015
21
0.210
Why?
Allografts
2
2019
171
0.200
Why?
Autoantibodies
1
2021
119
0.200
Why?
Protein Kinase Inhibitors
2
2018
67
0.200
Why?
Human papillomavirus 16
1
2019
8
0.190
Why?
Age Factors
4
2018
943
0.190
Why?
Papillomavirus Infections
2
2016
38
0.190
Why?
Nephrotic Syndrome
1
2019
38
0.190
Why?
Taxoids
2
2015
16
0.190
Why?
Biopsy, Fine-Needle
1
2019
54
0.190
Why?
Neoplasms
1
2022
280
0.190
Why?
Congo Red
1
2018
2
0.180
Why?
Tongue Neoplasms
1
2018
17
0.180
Why?
Small Cell Lung Carcinoma
1
2018
13
0.180
Why?
Antibodies, Monoclonal
2
2018
301
0.180
Why?
Registries
2
2022
214
0.170
Why?
Immunoglobulin G
1
2018
134
0.170
Why?
Laser Capture Microdissection
2
2019
3
0.170
Why?
Breast Neoplasms
1
2022
442
0.170
Why?
Palliative Care
2
2015
146
0.160
Why?
Quality of Life
2
2019
663
0.150
Why?
Immunoglobulins
1
2015
35
0.150
Why?
Robotic Surgical Procedures
1
2015
22
0.140
Why?
Prostaglandins
1
2014
4
0.140
Why?
Multiple Myeloma
2
2012
37
0.140
Why?
Nephritis, Interstitial
1
2014
6
0.140
Why?
Actuarial Analysis
1
2014
12
0.140
Why?
Academies and Institutes
1
2014
12
0.140
Why?
Cancer Care Facilities
1
2014
6
0.140
Why?
Propensity Score
1
2014
54
0.130
Why?
Preoperative Care
1
2015
146
0.130
Why?
Parotid Gland
1
2014
17
0.130
Why?
Gene Expression Regulation, Neoplastic
2
2015
136
0.130
Why?
Predictive Value of Tests
3
2015
637
0.130
Why?
Lymphatic Metastasis
1
2014
107
0.130
Why?
Intercellular Signaling Peptides and Proteins
1
2014
59
0.130
Why?
Health Services Accessibility
1
2014
113
0.120
Why?
Sulfonamides
2
2014
64
0.120
Why?
Logistic Models
1
2014
479
0.120
Why?
Spectrometry, Mass, Electrospray Ionization
1
2012
2
0.120
Why?
Prospective Studies
1
2018
1934
0.120
Why?
Tandem Mass Spectrometry
1
2012
22
0.120
Why?
Lymphoma
1
2012
56
0.120
Why?
Immunoglobulin Heavy Chains
1
2011
6
0.120
Why?
Papillomaviridae
3
2016
30
0.120
Why?
Prevalence
1
2014
544
0.120
Why?
Paraproteinemias
1
2011
5
0.120
Why?
Class I Phosphatidylinositol 3-Kinases
1
2011
11
0.120
Why?
Fluorescent Antibody Technique
3
2019
84
0.110
Why?
Proteins
1
2012
94
0.110
Why?
Myeloproliferative Disorders
1
2011
6
0.110
Why?
Young Adult
5
2018
2277
0.110
Why?
Patient Selection
3
2021
264
0.110
Why?
Vascular Diseases
1
2011
59
0.110
Why?
Xanthine Dehydrogenase
1
2010
7
0.100
Why?
Apoptosis Regulatory Proteins
1
2010
22
0.100
Why?
Time Factors
4
2019
1902
0.100
Why?
Calcium-Calmodulin-Dependent Protein Kinases
1
2010
28
0.100
Why?
Tumor Suppressor Proteins
1
2010
42
0.100
Why?
Risk Factors
4
2019
2664
0.100
Why?
Clinical Trials, Phase II as Topic
1
2009
30
0.100
Why?
Clinical Trials, Phase III as Topic
1
2009
29
0.100
Why?
Glomerular Filtration Rate
3
2015
77
0.100
Why?
Radiotherapy
1
2009
65
0.090
Why?
Signal Transduction
1
2012
588
0.090
Why?
Disease Progression
3
2021
861
0.090
Why?
Peptic Ulcer
1
2008
8
0.090
Why?
In Situ Hybridization
1
2008
63
0.090
Why?
DNA Methylation
1
2010
168
0.090
Why?
Antibodies, Antineutrophil Cytoplasmic
2
2019
10
0.080
Why?
Pyrazoles
1
2008
55
0.080
Why?
Risk Assessment
3
2019
806
0.080
Why?
Mass Spectrometry
2
2019
43
0.080
Why?
Blood Group Incompatibility
1
2005
2
0.080
Why?
Splenectomy
1
2005
8
0.080
Why?
ABO Blood-Group System
1
2005
7
0.080
Why?
Sensitivity and Specificity
2
2019
580
0.080
Why?
Kidney Failure, Chronic
2
2021
176
0.070
Why?
Graft Rejection
1
2005
84
0.070
Why?
Lymph Nodes
2
2016
84
0.070
Why?
Cyclin-Dependent Kinase Inhibitor p16
2
2018
25
0.070
Why?
Case-Control Studies
3
2012
687
0.070
Why?
Creatinine
2
2015
59
0.070
Why?
Drug Administration Schedule
2
2015
257
0.070
Why?
Adolescent
3
2018
2667
0.070
Why?
Radiotherapy Dosage
2
2015
149
0.070
Why?
Recurrence
2
2018
389
0.070
Why?
Etoposide
2
2015
64
0.070
Why?
Carboplatin
2
2015
52
0.070
Why?
Microscopy, Electron
2
2015
100
0.070
Why?
Paclitaxel
2
2015
80
0.060
Why?
Tumor Microenvironment
1
2022
16
0.060
Why?
Minnesota
2
2012
12
0.060
Why?
Analysis of Variance
2
2015
364
0.060
Why?
Kidney Function Tests
2
2012
29
0.060
Why?
Proportional Hazards Models
2
2014
390
0.060
Why?
Phototherapy
1
2021
39
0.060
Why?
C-Reactive Protein
1
2022
134
0.060
Why?
Antigens, Neoplasm
1
2021
53
0.050
Why?
Proteinuria
2
2012
116
0.050
Why?
Observer Variation
1
2021
146
0.050
Why?
Genetic Heterogeneity
1
2019
8
0.050
Why?
Phenotype
1
2021
379
0.050
Why?
Reference Values
1
2019
260
0.050
Why?
Neoplasm Invasiveness
1
2018
104
0.040
Why?
Graft Survival
1
2018
111
0.040
Why?
Radiation Pneumonitis
1
2015
4
0.040
Why?
Hemoptysis
1
2015
9
0.040
Why?
Esophagitis
1
2015
11
0.040
Why?
Cough
1
2015
12
0.040
Why?
Markov Chains
1
2015
32
0.040
Why?
Quality-Adjusted Life Years
1
2015
25
0.040
Why?
Chest Pain
1
2015
23
0.040
Why?
Paraffin Embedding
1
2015
5
0.040
Why?
Complement C3
1
2015
10
0.040
Why?
Tissue Fixation
1
2015
11
0.040
Why?
Radiotherapy, Adjuvant
1
2015
84
0.040
Why?
Dyspnea
1
2015
35
0.040
Why?
False Positive Reactions
1
2015
40
0.040
Why?
Neoplasm, Residual
1
2015
10
0.040
Why?
Radiation Injuries
1
2015
44
0.040
Why?
Lymph Node Excision
1
2015
37
0.040
Why?
Diagnostic Errors
1
2015
48
0.040
Why?
Cost-Benefit Analysis
1
2015
153
0.040
Why?
Guanine
1
2014
11
0.040
Why?
Glutamates
1
2014
19
0.040
Why?
Pyrroles
1
2014
22
0.040
Why?
Proton Pump Inhibitors
1
2014
15
0.040
Why?
Steroids
1
2014
30
0.030
Why?
Glomerular Basement Membrane
1
2014
2
0.030
Why?
Carcinoma
1
2015
84
0.030
Why?
Antibodies
1
2014
72
0.030
Why?
Mobility Limitation
1
2015
100
0.030
Why?
Autoimmune Diseases
1
2014
66
0.030
Why?
Acute Disease
1
2014
254
0.030
Why?
Patient Readmission
1
2015
129
0.030
Why?
Radiotherapy Planning, Computer-Assisted
1
2014
78
0.030
Why?
Diet
1
2015
202
0.030
Why?
Double-Blind Method
1
2014
559
0.030
Why?
Laser Therapy
1
2012
17
0.030
Why?
Sequence Analysis, Protein
1
2012
5
0.030
Why?
Length of Stay
1
2015
377
0.030
Why?
Heavy Chain Disease
1
2011
2
0.030
Why?
Electrophoresis
1
2011
23
0.030
Why?
Sex Distribution
1
2012
89
0.030
Why?
Age Distribution
1
2012
110
0.030
Why?
Amino Acid Sequence
1
2012
254
0.030
Why?
Molecular Sequence Data
1
2012
315
0.030
Why?
Biopsy, Needle
1
2012
117
0.030
Why?
Polycythemia Vera
1
2011
5
0.030
Why?
Thrombocythemia, Essential
1
2011
2
0.030
Why?
Primary Myelofibrosis
1
2011
5
0.030
Why?
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
2011
14
0.030
Why?
Child, Preschool
1
2014
786
0.030
Why?
Activities of Daily Living
1
2015
495
0.030
Why?
Stem Cell Transplantation
1
2011
54
0.030
Why?
Transplantation, Autologous
1
2011
223
0.030
Why?
Anti-Bacterial Agents
1
2014
412
0.030
Why?
Academic Medical Centers
1
2012
158
0.030
Why?
Gene Amplification
1
2010
28
0.030
Why?
Echocardiography
1
2011
197
0.030
Why?
Monomeric GTP-Binding Proteins
1
2010
4
0.030
Why?
Death-Associated Protein Kinases
1
2010
5
0.030
Why?
DNA Modification Methylases
1
2010
6
0.030
Why?
DNA Repair Enzymes
1
2010
9
0.030
Why?
Multivariate Analysis
1
2011
390
0.030
Why?
Remission Induction
1
2010
119
0.030
Why?
Immunoenzyme Techniques
1
2010
54
0.030
Why?
In Situ Hybridization, Fluorescence
1
2010
42
0.030
Why?
Glomerulosclerosis, Focal Segmental
1
2011
86
0.030
Why?
Cadherins
1
2010
38
0.030
Why?
CpG Islands
1
2010
53
0.030
Why?
Neoplasm Proteins
1
2010
60
0.020
Why?
Comorbidity
1
2012
562
0.020
Why?
Promoter Regions, Genetic
1
2010
108
0.020
Why?
Antigens, CD
1
2010
106
0.020
Why?
Adaptor Proteins, Signal Transducing
1
2010
94
0.020
Why?
Algorithms
1
2012
412
0.020
Why?
Lung
1
2010
171
0.020
Why?
Child
1
2014
1572
0.020
Why?
Smoking
1
2010
202
0.020
Why?
Tomography, X-Ray Computed
1
2014
891
0.020
Why?
Clinical Trials as Topic
1
2010
378
0.020
Why?
Severity of Illness Index
1
2012
1240
0.020
Why?
Transplantation Conditioning
1
2005
40
0.020
Why?
Drug Therapy, Combination
1
2005
265
0.020
Why?
Tissue Donors
1
2005
79
0.020
Why?
Animals
1
2010
5312
0.010
Why?
Fidler's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description